A phase III trial in patients with hepatocellular carcinoma (IMbrave150) has shown that the combined use of atezolizumab, classified as an ICI, and bevacizumab, classified as a vascular endothelial growth factor (VEGF) inhibitor, extended both PFS and OS compared to the use of atezolizumab alone [19]. Here, VEGFA is linked to hepatocellular carcinoma.